Patients with a history of allergic reaction to irinotecan, cephalosporins or a severe penicillin allergy are not eligible
Prior allergic reaction to the hormones involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
Patients who are allergic to milk
Must not have known allergic reaction against any of the components of the study treatment
Previous allergic reaction to an immunomodulatory drug (IMiD)
Use of steroids for non-tumor indications (for example: asthma or severe allergic reaction) is permitted
History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
Patients may not have a history of allergic reaction or hypersensitivity to microcrystalline cellulose (Avicel PH302) or polysorbate 80 (Tween 80), which are components of the drug product MGCD516
History of allergic reaction to docetaxel
Any history of allergic reaction to chemotherapies used
History of allergic reaction to alpha-1-antitrypsin.
Patients with hypersensitivity or other allergic reaction to platinum chemotherapy.
Patients with hypersensitivity or other allergic reaction to taxanes.
Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
History of allergic reaction (including erythema nodosum) to lenalidomide
Allergic reaction to single-agent rucaparib or irinotecan
Prior allergic reaction or known intolerance to irinotecan
If in Arm G, significant allergic reaction to cisplatin.
Prior allergic reaction to cisplatin
Patients with a history of severe allergic reaction to cisplatin or carboplatin
Patient with prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
History of anaphylaxis or serious allergic reaction to carboplatin or paclitaxel
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
Prior allergic reaction to cisplatin
History of allergic reaction to interleukin-2 or nivolumab
Prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).
History of any serious adverse reaction or hypersensitivity to cytarabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
The subject has a history of serious allergic reaction to any substance, resulting in hospitalization or requiring other emergent medical attention
History of allergic reaction to DSF or Cu
Allergic to temozolomide (TMZ)
History of allergic reaction to intravenous iodinated contrast media is not contraindication to the study; patients with history of mild allergic reaction to iodinated contrast media will be premedicated with 40 mg of prednisone orally (p.o.) 12 and 2 hours (hrs) before the transarterial chemoperfusion treatment to prevent allergic reaction; patients with history of moderate and severe allergic reaction to iodinated contrast media or patients with history of mild allergic reaction to iodinated contrast media despite adequate premedication will undergo angiogram using carbon dioxide or a gadolinium based contrast agent
History of allergic reaction to natalizumab
Known serious allergic reaction to vandetanib or metformin
Prior allergic reaction to the study drug(s) involved in this protocol
Any allergic reaction to a previously administered monoclonal antibody or other therapeutic protein
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Prior allergic reaction to temozolomide
Previous severe or life-threatening allergic reaction with rituximab or known allergy to the compounds found in INCB7839
Prior allergic reaction to the hormones involved in this protocol
Patients with known history of allergic reaction to intravenous (IV) contrast material that is not amenable to pre-treatment by University of Alabama at Birmingham (UAB) protocol
History of Grade 3 or higher allergic reaction with prior asparaginase treatment,
No prior known allergic reaction to monoclonal antibodies
History of >= 2 allergic reaction or any grade anaphylactic reaction during prior administration of tocilizumab
Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies.
Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.
Previous allergic reaction to radioisotope bone tracers
Known history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysis
History of any hypersensitivity or allergic reaction to any beta lactam antibiotic, tazobactam, or any study therapy (IV or oral)
Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipients
Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication
Prior allergic reaction to cetuximab
History of severe allergic reaction, including erythema nodosum, to lenalidomide
Patients who are allergic to micafungin and/or voriconazole or any of their ingredients
Documented severe allergic reaction to intravenous (IV) iodinated contrast, specifically bronchospasm and anaphylaxis
Prior known allergic reaction to pembrolizumab or its excipients
Prior allergic reaction to cisplatin
Patients with any history of allergic reaction to paclitaxel or other taxanes or carboplatin
Prior allergic reaction to the study drug(s) involved in this protocol
Patients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate 80); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimus
History of clinically significant allergic reaction attributed to any injected\n             compound.
Prior allergic reaction to any of the study drugs involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to the study drugs involved in this protocol or to a monoclonal antibody
Known contraindication to dexamethasone (allergic reaction or systemic fungal infection)
Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
Known allergic reaction to any component of MEDI1873
Prior allergic reaction to cetuximab
History of significant adverse or allergic reaction to any component of G100 and, if enrolled in Part 2, anti-PD1 antibodies.
Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
Prior allergic reaction to the study drugs.
Prior allergic reaction to the study drugs involved in this protocol
Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX-0158 formulation.
Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
Has prior allergic reaction to bevacizumab
History of allergic reaction to parenteral administered recombinant protein product
Prior allergic reaction to the study drugs (cisplatin, mitomycin, fluorouracil [5FU]) involved in this protocol
Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin;
Prior allergic reaction to the drugs involved in this protocol
Patients with history of allergic reaction to metformin
Patients with history of allergic reaction to minocycline or to any of the tetracyclines
Prior allergic reaction to temozolomide
Prior allergic reaction to 5-FU or oxaliplatin
History of >= grade 3 allergic reaction to mFOLFOX6 (patients successfully desensitized to oxaliplatin are eligible or those willing to undergo desensitization during the first two cycles of mFOLFOX6 per institutional guidelines)
History of an allergic reaction or intolerance to irinotecan
History of allergic reaction (including erythema nodosum) to lenalidomide
Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
History of allergic reaction to docetaxel
History of allergic reaction to disulfiram
Any known contraindications to sorafenib including allergic reaction, pill-swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant gastrointestinal (GI) bleed within 30 days, metastatic brain disease, renal failure requiring dialysis
Prior allergic reaction to temozolomide.
Prior allergic reaction to the study drug (bevacizumab)
Hypersensitivity to the active substance or to any of the excipients for study drug BT062, or history of severe allergic or anaphylactic reaction to therapeutic proteins (e.g. reaction to vaccination or to biological therapy)
Known history of allergic reaction to cremophor/paclitaxel
Significant allergic reaction to iodinated contrast
Prior allergic reaction to trastuzumab for the treatment of metastatic breast cancer
Prior allergic reaction to the study drugs involved in this protocol
History of allergic reaction to ATRA
History of allergic reaction to dasatinib
Patients who have previously been administered basiliximab or who have had an allergic reaction to basiliximab or one of its components in the past will be excluded
History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis
Known contraindication to standard-of-care sorafenib including allergic reaction, pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant GI bleed within 30 days, renal failure including dialysis
History of allergic reaction to a structural compound or biological agent similar to TH-302
Prior allergic reaction to the study drug(s) involved in this protocol
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
History of serious allergic reaction to yeast or yeast-derived products, including known or suspected hypersensitivity reaction to sargramostim;
Experienced a Grade 3 or higher hypersensitivity reaction to monoclonal antibodies or other therapeutic proteins, and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-hydroxytryptamine (5-HT3) receptor antagonists, or corticosteroids;
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
History of an allergic reaction to Human Serum Albumin
History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy.
Patients with known allergic reaction to lamivudine or tenofovir DF
Known allergic reaction to nickel
History of allergic reaction to ivabradine
Patients with a history of allergic reaction to ropivacaine or other local amide anesthetics
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation
Porphyria (possibility of triggering a porphyric reaction)
No history of (H/O) allergic reaction to iron therapy
Allergic to yogurt
History of drug sensitivity or allergic reaction to alpha- or beta-blockers
Prior allergic reaction to memantine (memantine hydrochloride)
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation or to latex
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of the anesthetics or analgesics medications used in the study
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the medication used in the study
Patient with known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts
Allergic reaction to carbamazepine or oxcarbazepine (major histocompatibility complex, class I, B [HLA-B]*1502)
History of allergic or other adverse reaction to venlafaxine or SSRI’s
Patients with a history of a severe allergic reaction (anaphylaxis)
History of drug sensitivity or allergic reaction to alpha or beta-blockers
History of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents
History of severe allergic reaction to obinutuzumab
A history of adverse reaction to IV thiamine
Not be allergic to any cruciferous vegetables (e.g.: broccoli, cauliflower, kale, brussels sprouts, arugula/rocket, bok choy, etc.)
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Allergic reaction to omeprazole
Allergic reaction to vitamin D
Allergic reaction to metformin
Any known allergic reaction to vaccine components
Patients with a known history of allergic reaction to ethanol, nitroglycerin, or citrate
life threatening allergic reaction to food and/or drugs
History of reaction to ICG, iodides, or technetium radiocolloid
Patient not able to tolerate MRI scan due to claustrophobia or severe pain or allergic reaction to contrast
Patients with renal failure or history of allergic reaction to Gadavist will be excluded
Known history of allergic reaction to magnetic resonance (MR) contrast material
Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
Previous allergic reaction to contrast medium
Allergic to common dentifrice ingredients
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Patients with a history of allergic reaction to latex or gadolinium containing intravenous contrast agents
History of severe allergic/hypersensitivity reaction or significant transfusion reaction.
Patients who have had an adverse reaction to oxytocin
Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides
History of allergic reaction to MR contrast media
History of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)
History of severe allergic-like reaction to iodinated contrast media
